ATE236161T1 - Purinderivate und verfahren zu ihrer herstellung - Google Patents

Purinderivate und verfahren zu ihrer herstellung

Info

Publication number
ATE236161T1
ATE236161T1 AT96934774T AT96934774T ATE236161T1 AT E236161 T1 ATE236161 T1 AT E236161T1 AT 96934774 T AT96934774 T AT 96934774T AT 96934774 T AT96934774 T AT 96934774T AT E236161 T1 ATE236161 T1 AT E236161T1
Authority
AT
Austria
Prior art keywords
production
purine derivatives
purine
derivatives
Prior art date
Application number
AT96934774T
Other languages
German (de)
English (en)
Inventor
Juerg Zimmermann
Hans-Georg Capraro
Patricia Imbach
Pascal Furet
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE236161T1 publication Critical patent/ATE236161T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96934774T 1995-11-01 1996-10-22 Purinderivate und verfahren zu ihrer herstellung ATE236161T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH309495 1995-11-01
CH221396 1996-09-10
PCT/EP1996/004573 WO1997016452A1 (en) 1995-11-01 1996-10-22 Purine derivatives and processes for their preparation

Publications (1)

Publication Number Publication Date
ATE236161T1 true ATE236161T1 (de) 2003-04-15

Family

ID=25689809

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96934774T ATE236161T1 (de) 1995-11-01 1996-10-22 Purinderivate und verfahren zu ihrer herstellung

Country Status (13)

Country Link
US (1) US7091346B1 (https=)
EP (1) EP0874846B1 (https=)
JP (2) JP4004066B2 (https=)
CN (1) CN1066147C (https=)
AR (1) AR004134A1 (https=)
AT (1) ATE236161T1 (https=)
AU (1) AU7296896A (https=)
BR (1) BR9611157A (https=)
CA (1) CA2234609C (https=)
DE (1) DE69627195T2 (https=)
ES (1) ES2196181T3 (https=)
PT (1) PT874846E (https=)
WO (1) WO1997016452A1 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6794390B2 (en) * 1996-08-02 2004-09-21 Cv Therapeutics, Inc. Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
CA2297967A1 (en) 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
US6573044B1 (en) 1997-08-07 2003-06-03 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
NZ503788A (en) 1997-10-27 2002-11-26 Agouron Pharma 4-aminothiazole derivatives and their use as inhibitors of cyclin-dependent kinases
AU1631699A (en) * 1997-12-18 1999-07-05 E.I. Du Pont De Nemours And Company Cyclohexylamine arthropodicides and fungicides
US6642231B2 (en) * 1998-02-26 2003-11-04 Aventis Pharmaceuticals Inc. 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
DE69912248T2 (de) * 1998-02-26 2004-04-22 Aventis Pharmaceuticals Inc. 6,9-disubstituierte 2-[trans-(4-aminocyclohexyl)amino] purine
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
IL138044A0 (en) * 1998-02-26 2001-10-31 Aventis Pharma Inc 6,9-disubstituted 2-[trans- 4-aminocyclohexyl) amino] purines
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
ATE322494T1 (de) * 2000-01-07 2006-04-15 Universitaire Instelling Antwe Purin derivate, ihre herstellung und verwendung
WO2001082967A1 (fr) * 2000-04-28 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Compositions medicinales destinees a supprimer la production de ?-amyloide
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818642B1 (fr) 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
EP1399446B1 (en) 2001-06-27 2005-08-03 Cyclacel Limited 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders
CZ294535B6 (cs) * 2001-08-02 2005-01-12 Ústav Experimentální Botaniky Avčr Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
CA2450777C (en) 2001-08-10 2013-04-09 Novartis Ag Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
EP1578722A4 (en) * 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0219052D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
AR041292A1 (es) 2002-09-19 2005-05-11 Schering Corp Pirazolopiridinas como inhibidores de quinasa dependientes de ciclina
WO2004035132A2 (en) * 2002-10-15 2004-04-29 Irm Llc Compositions and methods for inducing osteogenesis
JP2006521398A (ja) * 2003-03-28 2006-09-21 サイオス・インコーポレーテツド TGFβの二−環式ピリミジン阻害剤
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
JP5400388B2 (ja) * 2005-12-15 2014-01-29 ライジェル ファーマシューティカルズ, インコーポレイテッド キナーゼインヒビターおよびその利用
BRPI0720264B1 (pt) * 2006-12-08 2022-03-03 Novartis Ag Compostos e composições como inibidores de proteína cinase
EP2311807B1 (en) 2006-12-08 2015-11-11 Novartis AG Compounds and composition as protein kinase inhibitors
EP2132208A1 (en) * 2007-03-28 2009-12-16 NeuroSearch AS Purinyl derivatives and their use as potassium channel modulators
JP2010522719A (ja) * 2007-03-28 2010-07-08 ノイロサーチ アクティーゼルスカブ プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
CZ302225B6 (cs) * 2007-07-04 2010-12-29 Univerzita Palackého v Olomouci Substituované 6-anilinopurinové deriváty jako inhibitory cytokinin oxidasy a prípravky obsahující tyto slouceniny
US8592432B2 (en) * 2008-04-07 2013-11-26 Bei Chen Compounds and compositions as protein kinase inhibitors
EP2344501A1 (en) * 2008-09-26 2011-07-20 NeuroSearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
WO2010034707A1 (en) 2008-09-26 2010-04-01 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
BR112013023050A8 (pt) 2011-03-09 2018-09-25 G Pestell Richard antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um composto candidato, para produzir in vitro células epiteliais primárias, para diagnosticar câncer de próstata, para selecionar um tratamento para um indivíduo tendo um câncer/tumor de próstata, linhagem de célula, e, modelo animal
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
AU2013262977A1 (en) 2012-05-14 2015-01-22 Prostagene, Llc Using modulators of CCR5 for treating cancer
CA2876780A1 (en) 2012-06-26 2014-01-03 Saniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
CN105283206B (zh) * 2013-03-27 2019-11-08 财团法人峨山社会福祉财团 包含p34的表达抑制剂或活性抑制剂作为有效成分的用于治疗或转移抑制癌的组合物
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US11920164B2 (en) 2014-07-30 2024-03-05 Yeda Research And Development Co. Ltd. Media for culturing naive human pluripotent stem cells
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
HK1246645A1 (zh) * 2015-03-27 2018-09-14 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
EP3347018B1 (en) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN114149432B (zh) * 2016-09-30 2024-07-05 斯坦福国际研究院 用于癌症治疗的双重clk/cdk1抑制剂
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
WO2020152686A1 (en) 2019-01-23 2020-07-30 Yeda Research And Development Co. Ltd. Culture media for pluripotent stem cells
CN120289460A (zh) * 2024-01-09 2025-07-11 中国科学院合肥物质科学研究院 含有嘌呤环的化合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3529497A1 (de) 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
AU626983B2 (en) 1989-01-31 1992-08-13 Whitby Research, Inc. N6-substituted 9-methyladenines
EP0625158B1 (en) * 1992-01-06 1999-03-31 The Wellcome Foundation Limited Therapeutic nucleosides of the 2',3'-dideoxy-3'-fluoro-purine series
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US5753635A (en) 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
AU4920397A (en) 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
EP1578722A4 (en) * 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
WO2004035132A2 (en) * 2002-10-15 2004-04-29 Irm Llc Compositions and methods for inducing osteogenesis

Also Published As

Publication number Publication date
WO1997016452A1 (en) 1997-05-09
US7091346B1 (en) 2006-08-15
JP4004066B2 (ja) 2007-11-07
CN1066147C (zh) 2001-05-23
ES2196181T3 (es) 2003-12-16
AU7296896A (en) 1997-05-22
CA2234609A1 (en) 1997-05-09
CN1202896A (zh) 1998-12-23
DE69627195D1 (de) 2003-05-08
EP0874846A1 (en) 1998-11-04
JP2007231023A (ja) 2007-09-13
AR004134A1 (es) 1998-09-30
EP0874846B1 (en) 2003-04-02
BR9611157A (pt) 1999-03-30
DE69627195T2 (de) 2004-01-29
JPH11514336A (ja) 1999-12-07
CA2234609C (en) 2006-11-28
PT874846E (pt) 2003-08-29
HK1016580A1 (en) 1999-11-05

Similar Documents

Publication Publication Date Title
ATE236161T1 (de) Purinderivate und verfahren zu ihrer herstellung
DE59606535D1 (de) Furnacerusse und Verfahren zu ihrer Herstellung
DE59602652D1 (de) Zahnbürste und verfahren zu ihrer herstellung
DE69616717D1 (de) Berührungssensoren und verfahren zu ihrer herstellung
DE69530989D1 (de) Neue pyrimidinderivate und verfahren zu ihrer herstellung
DE69624457D1 (de) ArOMATIsIERTE PRODUKTE UND VERFAHREN ZU IHRER HERSTELLUNG
ATA902992A (de) Antigeschwulstmittel und verfahren zu ihrer herstellung
DE69211697D1 (de) Antischmelzsicherungsstruktur und verfahren zu ihrer herstellung
DE69624981D1 (de) Solarzelle und Verfahren zu ihrer Herstellung
DE59603578D1 (de) Flachdichtung und verfahren zu ihrer herstellung
ATA216291A (de) Reflektierende erzeugnisse und verfahren zu ihrer herstellung
DE69625176D1 (de) Camptothecin-derivate und verfahren zu ihrer herstellung
DE69608359D1 (de) Hexaazaisowurtzitan-derivate und verfahren zu deren herstellung
EP0801071A4 (en) LEWIS DERIVATIVE X AND PRODUCTION METHOD THEREOF
ATE231840T1 (de) Pyrrolidinylhydroxamsäuren und verfahren zu ihrer herstellung
DE69433296D1 (de) Eisen-lactoferrin kombination und verfahren zu ihrer herstellung
DE69622368D1 (de) Schwefelverbindungen und verfahren zu ihrer herstellung
DE59606076D1 (de) Bürste und Verfahren zu ihrer Herstellung
DE69510774D1 (de) Katschukzusammensetzung und verfahren zu ihrer herstellung
DE69603515D1 (de) Aktivkohle und Verfahren zu ihrer Herstellung
DE69801795D1 (de) Indolyl-pyrrolylidenmethylpyrrol-derivate und verfahren zu ihrer herstellung
DE59610554D1 (de) Felge und Verfahren zu ihrer Herstellung
DE69614524D1 (de) Etherverbindungen und verfahren zu ihrer herstellung
DE69523571D1 (de) Pyridylimidazol-derivate und verfahren zu ihrer herstellung
DE69612927D1 (de) Kupplung und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0874846

Country of ref document: EP

REN Ceased due to non-payment of the annual fee